Vicore Pharma
vicorepharma.com
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Vicore Pharma to Participate in the Chardan Healthcare Conference
STOCKHOLM, SE / ACCESS Newswire / October 13, 2026 / AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Chardan Healthcar
Read more
Report
Increase in number of shares and votes in Vicore Pharma
Stockholm, Sweden & Cambridge, Mass. September 30, 2026 - Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the numb
Read more
Report
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the compa
Read more
Report
Vicore Pharma to Participate in the Leerink Therapeutics Forum
STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs),
Read more
Report
Vicore Pharma to Commence Trading in the United States on The Nasdaq Stock Market
Stockholm, Sweden & Cambridge, Mass., July 1, 2026 - Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel…
Read more
Report